Wegovy vs. Mounjaro
Adipositas-Zulassung vs. T2D-Zulassung – Der Vergleich
Wegovy ist spezifisch für Adipositas zugelassen. Mounjaro ist für Typ-2-Diabetes zugelassen, wird aber aufgrund der starken SURMOUNT-Daten häufig zur Gewichtsreduktion in Betracht gezogen.
Wirkungsweise
- →GLP-1-Rezeptor-Agonist
- →Zugelassen für Adipositas (BMI ≥30)
- →Reduziert MACE-Risiko um 20% (SELECT-Studie)
- →Dualer GIP + GLP-1-Agonist
- →Zugelassen für T2D (Zepbound für Adipositas)
- →Stärkerer Gewichtsverlust in Studien (~21%)
Head-to-Head Comparison
| Factor | Wegovy | Mounjaro |
|---|---|---|
| Active molecule | Semaglutide | TirzepatideBest |
| Receptor targets | GLP-1 only | GIP + GLP-1 |
| FDA obesity approval | Yes (June 2021) | No — Zepbound brand for obesity |
| Max dose | 2.4 mg weekly | 15 mg weekly |
| Weight loss (STEP-1/SURMOUNT-1) | 14.9% at 68 wks | 20.9% at 72 wks |
| Nausea incidence | ~44% (STEP-1) | ~31% (SURMOUNT-1 15 mg) |
| Cardiovascular outcome trial | SELECT 2023: 20% MACE reduction | SURPASS-CVOT 2024: 15% MACE reduction |
| Off-label use for weight loss | N/A — on label | Common when Zepbound not covered |
| Monthly cost (uninsured) | ~$1,300–1,400 | ~$1,000–1,200 |
| T2D brand | Ozempic | Mounjaro |
Weight Loss: The Numbers
Choose Based on Your Goal
Maximum weight loss
Tirzepatide (Mounjaro/Zepbound) shows ~20.9% vs Wegovy's 14.9% in individual trials, and is directly superior in SURMOUNT-5 (2025).
On-label obesity treatment
Wegovy is specifically FDA-approved for obesity. If your primary diagnosis is obesity, Wegovy (or Zepbound for tirzepatide) is on-label.
Cardiovascular risk reduction
Wegovy's SELECT trial (2023) showed a 20% MACE reduction in obesity + CVD. Mounjaro's SURPASS-CVOT (2024) showed 15%. Both have positive CV data.
Lower nausea rates
Trial data suggests tirzepatide has lower nausea (~31% vs ~44% for semaglutide). GIP modulation may reduce GI side effects.
Insurance coverage
Mounjaro for T2D has better insurance coverage than Wegovy for obesity. If you have T2D, Mounjaro may be more accessible.
You want the obesity-approved obesity drug
For pure on-label obesity pharmacotherapy, compare Wegovy vs Zepbound (the obesity-approved tirzepatide brand).
Which Is Right for You?
For maximum weight loss, tirzepatide has consistently outperformed semaglutide in head-to-head data. SURMOUNT-5 (2025) directly compared them and found tirzepatide produced ~47% more relative weight loss. If maximum weight reduction is the priority and you have T2D or your plan covers Zepbound, tirzepatide is the evidence-based choice.
Wegovy has two key advantages: it is on-label for obesity (giving prescribers and patients confidence), and the SELECT trial showed a 20% MACE reduction in obesity with CVD — currently the strongest cardiovascular outcome data for an obesity drug. Mounjaro's SURPASS-CVOT (2024) showed 15% MACE reduction but in a T2D population.
For patients without T2D who are choosing between Wegovy and Mounjaro specifically, note that Mounjaro's obesity data comes from SURMOUNT trials under the Zepbound brand — the Mounjaro label is for T2D. Your prescriber can prescribe Mounjaro off-label for weight loss, but Zepbound is the indicated brand for that purpose.
Wegovy vs Mounjaro: Häufig gestellte Fragen
Ja, laut Studiendaten erreicht Tirzepatid (Mounjaro) im Durchschnitt eine höhere Gewichtsreduktion.
Wegovy oder Mounjaro in Shotlee tracken
Protokolliere Dosen, Gewichtsverlauf und Nebenwirkungen für beide Medikamente. Kostenlos für iOS und Android.